Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
7 Countries Where Newcomers Feel Most Welcome, and 3 Where They Often Don’t - 2The 15 Best Business visionaries Under 40
- 3From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
- 4Keep It Cool: Uncovering Famous Fridge Brands for Each Home
- 5Dependable Savvy Locks to Update Your Home Security
- How to disinfect if the stomach bug hits your home
- Manual for Picking Coastline Travel
- ADHD drugs work, but not the way experts thought
- Am I a Summer, or is this a scam? What I learned from color analysis.
- Tech for Wellbeing: Applications and Devices for a Better You
- Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan
- Magnetic fossils may reveal ancient creature's internal 'GPS system'
- Why most Jewish Israelis back the death penalty for terrorists
- Jeff Bezos’ Blue Origin launches landmark Mars mission in New Glenn rocket’s first big test
